CREATING SOLUTIONS AND RESTORING LIVES
Addiction is a chronic, relapsing brain disease that can be treated; Yet unlike other chronic brain diseases, only a fraction of individuals with a substance use disorder receive any form of treatment.
Substance use disorders affect a large amount of the U.S. population. Over 40 million people in the U.S. had a Substance Use Disorder in the past year, including 28.3 million with an Alcohol Use Disorder (AUD), 2.7 million with an Opioid Use Disorder (OUD) and 1.3 million with a Cocaine Use Disorder (CUD).
Of these 40 million people in need of treatment, only 2.6 million received any, leaving 9 out of 10 people in need of treatment without effective care.
There are no medications approved by the FDA to treat Stimulant Use Disorders like Cocaine Use Disorder, and no new treatments have been approved by the FDA to treat Alcohol Use Disorder in the last 16 years.
1
The addiction crisis is deadlier than ever. Overdoses are now the leading cause of accidental death in the United States and have increased devastatingly during the COVID-19 era.
According to the CDC, there were more than 107,000 fatal overdoses in the United States in 2021, the highest number of overdose deaths ever recorded in a single year.
Additionally, in 2021, more than 140,000 deaths in the U.S. were related to excessive alcohol use making alcohol the third largest preventable cause of death in the nation.
At Tempero Bio, we’re committed to translating science into innovative medicines that will change the course of treatment in substance use disorders and in turn, revitalize millions of lives.
3
2
-
Substance Abuse and Mental Health Services Administration (2020). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey of Drug Use and Health https://www.samhsa.gov/data/release/2020-national-survey-drug-use-and-health-nsduh-releases
-
CDC https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
-
Alcohol and Public Health - Deaths from Excessive Alcohol Use in the United States https://www.cdc.gov/alcohol/features/excessive-alcohol-deaths.html
Our Focus
At Tempero Bio, we’re focused on advancing transformative therapies that treat and prevent substance use disorders and recover lives.
Our lead therapeutic drug candidate, TMP-301, is a potent, orally-available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) that is being investigated for the treatment of Substance Use Disorders, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD). Additional discovery is also underway on the potential of TMP-301 to treat other addictive disorders such as Opioid Use Disorder (OUD) and Polysubstance Use Disorder (PUD).
According to the 2020 National Survey on Drug Use and Health, over 40 million people aged 12 or older (14.9%) had a substance use disorder, including alcohol (28.3 million), opioid (2.7 million), and cocaine (1.3 million) use.
Only 2.6 million people (6.5%) suffering from a substance use received any treatment – creating a disparity that is having devastating consequences, including rising deaths from drug overdoses.
Our team is acting with urgency to deliver new medical solutions that are desperately needed to help close the treatment gap in substance use disorders and address the devastating addiction epidemic in our society.
Lorem ipsum dolor sit met
Our Approach
Glutamate is an important neurotransmitter that is present in a large majority of all brain synapses, plays an essential role in normal brain functioning, and whose levels must be tightly regulated.
Alterations in glutamate signaling, including metabotropic glutamate receptor 5 (mGluR5), are associated with a range of neurological disorders, such as addiction.
TMP-301 is a selective mGlurR5 negative allosteric modulator (NAM) designed to reduce excessive glutamate signaling, offering potential as a novel therapeutic in areas of high unmet treatment need in substance use disorders.
TMP-301 has a mechanism of action validated in preclinical and initial clinical studies to dampen – but not block – glutamate signaling in specific brain regions associated with substance abuse.
Initially, TMP-301 is being studied as an mGlurR5 NAM in cocaine and alcohol use disorder, with continued discovery in opioid and polysubstance use disorders.
Our Pipeline
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Cocaine Use Disorder (CUD)
Alcohol Use Disorder (AUD)
Opioid Use Disorder (OUD)
Polysubstance Use Disorder (PUD)
Our Team
We have assembled an experienced leadership team to lead the effort for Tempero Bio.
LEADERSHIP
SCIENTIFIC ADVISORS
Connect with us.